POLISCOPE
Back to bills

The civic record

Read. Follow. Verify.
Did Not Advance

Arizona Senate Bill 1542 appropriates $10 million for PTSD clinical trials using midomafetamine and…

Original title: controlled substances; approval; use; research

Last action · February 18, 2026: DPSponsor: Kevin Payne

Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Public stanceCommunity reactions are separate from the official record and reporting.

What This Bill Proposed

Senate Bill 1542 appropriates $10 million in 2026-2027 to the Arizona Department of Health Services for grants supporting clinical trials, research, and clinician training on using to treat post-traumatic stress disorder in first responders and veterans. The bill also conditionally requires employers to provide workers' compensation coverage for one complete course of midomafetamine treatment for firefighters and certified peace officers diagnosed with PTSD, provided federal approval is granted by January 1, 2029.

Why it matters

Sets up state-funded research grants and potential insurance coverage rules for a specific psychedelic-assisted therapy for post-traumatic stress disorder, affecting state mental health budgets, public safety employers, and specialized medical researchers.

Who It Would Have Affected

Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.

Directly affected

Firefighters

Professional firefighters diagnosed with PTSD may become eligible for workers' compensation coverage including one complete course of midomafetamine treatment if federal approval conditions are met.

Directly affected

Certified peace officers

Certified peace officers diagnosed with PTSD may become eligible for workers' compensation coverage including one complete course of midomafetamine treatment if federal approval conditions are met.

Directly affected

Arizona Department of Health Services

The department receives a $10,000,000 appropriation in fiscal year 2026-2027 to administer grant awards for clinical trials, research, and clinician training.

Directly affected

Public institutions of higher education

Public universities in Arizona delivering mental health care or clinical research may apply as lead applicants or partners for grant funding under the bill.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

Who is eligible to receive workers' compensation coverage for midomafetamine treatment under this bill?
Professional firefighters and certified peace officers who have been diagnosed with post-traumatic stress disorder by a licensed mental health professional and have an accepted workers' compensation claim for PTSD, subject to federal approval.
What is the purpose of the $10 million appropriation in the bill?
The funds are appropriated to the Arizona Department of Health Services to award grants for clinical trials, applied clinical research, and training of clinicians in the safe administration of to treat PTSD in first responders and veterans.
Are the provisions in this bill effective immediately?
No. Most major provisions, including workers' compensation coverage and controlled substance schedule updates, are conditional enactments that depend on specific federal FDA approvals and drug scheduling actions occurring by January 1, 2027 or January 1, 2029.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

This bill did not become law - Died at adjournment · in Senate committee.

Procedural history

3 actions
  1. Feb 18, 2026SenateCommittee
    DP
  2. Feb 3, 2026SenateFloor
    Senate Second Reading
  3. Feb 2, 2026SenateIntroduced
    Senate First Reading

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Lobbying Activity

No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Sponsors

Discoveries

1 pattern noticed across the record

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift100% confidence

Conditional Psychedelic Therapy Coverage

The measure ties state workers' compensation coverage and controlled substance rescheduling directly to future federal FDA approval milestones for midomafetamine.

Connected Entities

Arizona Department of Health Services, United States Drug Enforcement Administration, Industrial Commission of Arizona and 5 more
OrganizationArizona Department of Health Services“Recipient of the $10,000,000 appropriation to award grants for clinical trials a”Map →
OrganizationUnited States Drug Enforcement Administration“Federal agency responsible for rescheduling controlled substances”Map →
OrganizationIndustrial Commission of Arizona“Commission responsible for establishing treatment guidelines and reimbursement v”Map →
OrganizationArizona Legislative Council“Recipient of written notices regarding conditional enactments”Map →
OrganizationJoint Legislative Budget Committee“Recipient of the annual report on treatment costs submitted by the commission”Map →
OrganizationUnited States Food and Drug Administration“Federal agency whose approval of midomafetamine triggers conditional enactments”Map →
OrganizationArizona State Board of Pharmacy“Executive director is required to notify legislative officials regarding federal”Map →
PersonKevin Payne“Arizona State Senator who introduced SB 1542”Map →

Sources

Open source document

apps.azleg.gov

Analysis Score

0–100
  • Significance20
    Lowered because this bill did not pass (its text scored 75)
  • Controversy45
    Intensity of disagreement among stakeholders
  • Entertainment15
    Compellingness for a non-policy-wonk reader
  • Buzz50
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record